Attention is focusing on whether the criticism that biopharmaceuticals that treat osteoporosis by preventing bone absorption or activating bone formation are not fully enjoyed due to restrictions on Korea's benefit standards can be resolved. This is directly related to Amgen's Prolia (Denosumab) and Evenity (Romosumab) access to patients, as experts argued the need every year and the National Assembly also agreed, the government said it would consider reflecting it after collecting opinions.

On the 7th, the MOHW promised to improve the benefit standards reflecting the latest treatment guidelines at the "policy discussion on improving the treatment environment for osteoporosis" hosted by Rep. Lee Jong-su